<DOC>
	<DOCNO>NCT01709500</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , parallel-group , multi-national study alirocumab ( REGN727/SAR236553 ) patient Heterozygous Familial Hypercholesterolemia ( heFH ) adequately control Lipid-Modifying Therapy ( LMT ) .</brief_summary>
	<brief_title>Study Alirocumab ( REGN727/SAR236553 ) Patients With heFH ( Heterozygous Familial Hypercholesterolemia ) Who Are Not Adequately Controlled With Their LMT ( Lipid-Modifying Therapy )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patients heFH* adequately controlled** maximallytolerated daily dose*** statin without LMT , stable dose prior screen visit ( week 2 ) . *Diagnosis heFH must make either genotyping clinical criterion . For patient genotyped , clinical diagnosis may base either Simon Broome criterion definite FH ( Appendix 1 ) WHO/Dutch Lipid Network criterion score &gt; 8 point ( Appendix 2 ) . ** `` Not adequately control '' define LDLC ≥70 mg/dL ( 1.81 mmol/L ) screen visit ( week 2 ) patient history document CVD ( Appendix 3 ) , LDLC ≥100 mg/dL ( 2.59 mmol/L ) screen visit ( week 2 ) patient without history document CVD . *** `` Maximallytolerated dose '' define ( follow acceptable ) : Rosuvastatin 20 mg 40 mg daily Atorvastatin 40 mg 80 mg daily Simvastatin 80 mg daily ( already dose &gt; 1 year see exclusion criterion # 7 ) Note : Patients able statin dos treat dose daily atorvastatin , rosuvastatin , simvastatin consider appropriate patient , accord investigator 's judgment . Some example acceptable reason patient take low statin dose include , limited : adverse effect higher dos , advanced age , low body mass index , regional practice , local prescribe information , concomitant medication , comorbid condition impair glucose tolerance/impaired fast glucose . The reason ( ) document case report form ( CRF ) . 2 . Provide sign informed consent 1 . Patient without diagnosis heFH make either genotyping clinical criterion 2 . LDLC &lt; 70 mg/dL ( &lt; 1.81 mmol/L ) screen visit ( week2 ) patient history document cardiovascular disease 3 . LDLC &lt; 100 mg/dL ( &lt; 2.59 mmol/L ) screen visit ( week ‑2 ) patient without history document cardiovascular disease 4 . Not stable dose LMT ( include statin ) least 4 week and/or fenofibrate least 6 week , applicable , prior screen visit ( week 2 ) screen randomization 5 . Currently take another statin simvastatin , atorvastatin , rosuvastatin 6 . Simvastatin , atorvastatin , rosuvastatin take daily take register dose 7 . Daily dose atorvastatin 80 mg , rosuvastatin 40 mg , simvastatin 40 mg ( except patient simvastatin 80 mg 1 year , eligible ) 8 . Use fibrates , fenofibrate within 6 week screen visit ( week2 ) screen randomization visit 9 . Use nutraceutical product overthecounter therapy may affect lipid stable dose/amount least 4 week prior screen visit ( week 2 ) screen randomization visit 10 . Use red yeast rice product within 4 week screen visit ( week2 ) , screen randomization visit 11 . Patient receive plasmapheresis treatment within 2 month prior screen visit ( week 2 ) , plan receive study 12 . Recent ( within 3 month prior screen visit [ week 2 ] screen randomization visit ) MI , unstable angina lead hospitalization , percutaneous coronary intervention ( PCI ) , coronary artery bypass graft surgery ( CABG ) , uncontrolled cardiac arrhythmia , stroke , transient ischemic attack ( TIA ) , carotid revascularization , endovascular procedure surgical intervention peripheral vascular disease ( The inclusion/exclusion criterion provide intend contain consideration relevant participant 's potential participation clinical trial ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>